The objective of the study was to determine whether initiation of early phototherapy in positive direct Coombs' test (DCT) with ABO-incompatible newborns would prevent severe jaundice.
INTRODUCTION
Hyperbilirubinemia is a frequent cause of readmission to neonatal units. 1 In a retrospective analysis of readmitted neonates who had significant jaundice with total serum bilirubin (TSB) of Z340 mmol/l, ABO incompatibility was found as the main cause of readmission. 2 ABO incompatibility occurs in 20 to 25% of pregnancies and hemolytic disease develops in around 10% of such offspring. 3 A presumptive diagnosis of hemolysis is based on the presence of ABO incompatibility, unconjugated hyperbilirubinemia, a positive direct Coombs' test (DCT), spherocytes in the blood smear, increased reticulocytes, with extensive polychromasia and increased numbers of nucleated red blood cells. 3 Positive DCT, high reticulocyte count and positive family history of neonatal jaundice are strong predictors of hyperbilirubinemia in ABO-incompatible newborns. 4 It is also known that the risk of neonatal jaundice is four times higher in infants with positive DCT compared to those with negative DCT. 5 However, severe jaundice and even kernicterus can occur in some of these neonates with no apparent early findings of hemolysis. 6 Thus, early diagnosis and perhaps preventive treatment may be useful. Guidelines for phototherapy management in ABO incompatibility with positive DCT were previously published by Osborn et al. 7 In our unit, phototherapy is utilized when TSB is Z95% according to the time-based bilirubin nomogram. 8 Recently, Stanley et al. 9 reported that there was no evidence to suggest that phototherapy for neonatal hyperbilirubinemia had any long-term adverse neurodevelopmental effects. Efficacy of prophylactic phototherapy in babies with positive DCT and ABO incompatibility has been evaluated previously in two studies with inconclusive results. 10, 11 Phototherapy was initiated relatively late with mean age at study entry of more than 50 hours. The authors of one study 10 felt that poor response to phototherapy was related to a significant delay in starting the light therapy. We conducted this prospective, quasirandomized study to determine whether earlier initiation of prophylactic phototherapy prevents hyperbilirubinemia in ABO-incompatible newborns with positive Coombs' test.
METHODS

Participant Criteria
This study was performed between March 2001 and February 2003. The study was approved by the hospital research and ethical committee. According to our unit's policy, cord blood should be obtained from all newborns with group O mothers. The TSB, blood group, DCT, complete blood count (CBC) with smear and reticulocyte count were carried out on each sample.
Infants were eligible for enrolment into the study if they had completed 37 weeks of gestation and had a birth weight >2000 g, and if their blood group was either A, B or AB with positive DCT.
Exclusion criteria were (1) neonates having any illness that would require admission to the neonatal intensive care unit as respiratory distress requiring oxygen, (2) sepsis or severe congenital malformations, (3) infants with other causes of jaundice including breastfeeding jaundice, dehydration, cephalohematoma and (4) hemolytic diseases other than ABO incompatibility such as Rh incompatibility, minor blood group incompatibility or glucose-6-phosphate dehydrogenase (G6PD) deficiency. Informed consent was obtained from all parents before enrolling infants in the study.
Study Design
This was a prospective controlled study including all ABO-incompatible term newborns with positive DCT diagnosed within 4 hours of life. Infants were quasirandomized into two groups: the phototherapy prophylactic group (group I), which received phototherapy started within the first 4 hours of life until completed 24 hours of life, and the control group (group II), which did not receive prophylactic phototherapy. Selection of patients to either group was by 2-week alternative strategy; for example, Infants who were born in the first 2 weeks of this study were enrolled into group I, infants born in the second 2 weeks were enrolled into group II, next 2 weeks were assigned for group 1 and so on through out the study period.
The babies were placed in the incubator seminaked except for eye shield, 40 cm from the source of light, which was six fluorescent light tubes (four blues and two whites) (AMEDA Engell (EN 60 601-1), Hunenberg). Light tubes were tested for irradiance every 200 hours. Spectral irradiance is measured at multiple sites by a radiometer with desired values of 8 to 10 microwaves/cm 2 /nm. Adequate fluid intake was ensured by completing breast feeds with artificial feeds if necessary. CBC, reticulocyte count, and serum direct and indirect bilirubin levels were performed in all enrolled infants at 12, 24, 48, 72 and 96 hours of life. TSB was monitored every 4 hours for infants whose serum bilirubin was increasing in spite of phototherapy and in all neonates requiring intensive phototherapy.
Minor group identification and measurement of the G6PD were performed in the following conditions: high reticulocytes >6%, poor response to phototherapy when TSB Z20 mg/dl, or in infants who had family history of G6PD deficiency.
Serum bilirubin level was measured using a Diminsion bilirubinmeter (DADE Behring Diminsion RXL-France). Coombs' test was performed using the standard Direct Autoglobulin Test (DAT).
Hyperbilirubinemia was defined as TSB Z95th percentile according to the percentile-based hourly bilirubin nomogram. 10 Rescue phototherapy for infants in both groups was indicated in case of hyperbilirubinemia. Rescue phototherapy was discontinued whenever the TSB decreased 1 mg/dl below the 95th percentile. TSB levels were monitored after 12 and 24 hours of phototherapy discontinuation. Intensive phototherapy (Mediprema, GDE 1596, France) was indicated when TSB continued to increase in spite of initiation of standard phototherapy or if the serum bilirubin level is >20 mg/dl and just before preparing for exchange blood transfusion procedures. Our intensive phototherapy equipment usually provided >30 microwaves/cm 2 /nm. Exchange transfusions were performed in both groups when TSB exceeded 20 mg/dl (342 mmol/l) and did not decrease below that level within 4 hours of intensive phototherapy.
In all cases, the following was recorded: gender, birth weight, daily weight gain, gestational age, mode of delivery route, feeding pattern, Apgar scores, chronic maternal diseases (e.g. hypertension, diabetes mellitus, etc.) during pregnancy and whether there were any siblings with neonatal jaundice. According to our hospital policy, ABO-incompatible neonates who have positive DCT are discharged home at 48 hours if their TSB <95th percentile. For these babies, TSB was monitored at 72 and 96 hours of life in the pediatric ambulatory clinic. Prolonged hospital stay was defined as failure to discharge an infant by 48 hours of age because of hyperbilirubinemia requiring phototherapy.
Evaluation Criteria
Efficacy of prophylactic therapy was monitored by comparing the two groups on their major outcome variables such as daily TSB, number of hyperbilirubinemic neonates, number of infants who received intensive phototherapy or exchange transfusion, number of infants who had prolonged hospital stay or readmission after hospital discharge for jaundice.
Statistical data were analyzed with the independent t-test for continuous data and by w 2 analysis for categorical data. Significance of these tests was determined as p<0.05.
RESULTS
During the 2-year study period, a total of 9611 live-born term neonates were delivered at our institution. Of these, 1222 neonates (13%) had ABO incompatibility (mothers' blood group was O and their neonates were A, B or AB. From this population, 980 were excluded for the following reasons: 851 were negative Coombs' test, 63 were G6PD deficient, 53 had hemolytic disease due to Rh or minor group incompatibles and 13 patients due to incomplete data.
Our study population included 242 positive Coombs' ABOincompatible neonates. They were divided into two groups: 102 neonates were enrolled as the prophylactic phototherapy group (57% were maternal type O and infant type A, and 43% were maternal type O and infant type B) and 140 neonates were enrolled as the control group (81% type O and A, and 19% type O and B). No type O mother with an AB infant was found.
Perinatal characteristics of both groups are reported in Table 1 , with no significant differences.
Evaluation of Prophylactic Phototherapy
Prophylactic phototherapy during the first day of life was associated with a significant decrease in the TSB at 24 hours (p ¼ 0.002) and at 48 hours (p ¼ 0.003) but not at 72 and 96 hours ( Table 2 ). In order to evaluate the clinical significance of these results, we determined the number of neonates in each group who developed hyperbilirubinemia with TSB Z95th percentile at 24, 48 and 96 hours of life. At 24 hours of life, hyperbilirubinemia was detected in 15 patients (15%) in the prophylactic group compared with 45 controls (32%) (p ¼ 0.006).
All of the controls who required phototherapy did so in the first 24 hours with a mean age of 17±7 hours of life (ranging between 8 and 24 hours of life). With initiation of rescue phototherapy, the difference in number of hyperbilirubinemic patients was not significant at 48 hours (nine patients in the prophylactic group vs 18 controls) and at 96 hours, with seven patients in both groups.
The total number of infants who developed hyperbilirubinemia at any time during the first 96 hours was significantly lower in the prophylactic group with only 17 patients (17%) compared to 45 controls (32%) (p ¼ 0.006) ( Table 2 ). The number needed to be treated (NNT) for prevention of hyperbilirubinemia was 7. Three patients from the prophylactic group required intensive phototherapy compared to nine patients in the control group (p ¼ 0.21). Blood exchange transfusion was performed in three patients of the control group and none in the prophylactic group.
Prolonged hospital stay for more than 48 hours because of the need for rescue phototherapy was significantly lower in the prophylactic group with nine patients compared to 26 controls (p ¼ 0.03). Out of the 26 controls, 17 stayed between 49 and 72 hours, seven stayed >72 hours and <120 hours and the remaining two infants stayed >120 hours. Out of the nine Infants in the prophylactic group, six stayed between 49 and 72 hours and three stayed between 73 and 120 hours.
In an attempt for an early prediction of a group with positive Coombs' ABO-incompatible neonates who might develop significant jaundice, which would require rescue phototherapy and prolonged hospital stay, we analyzed the data of the 26 patients from the control group who had prolonged hospital stay Z48 hours for rescue phototherapy. Table 3 summarizes the accuracy of different tests for early prediction of hyperbilirubinemia.
DISCUSSION
Prophylactic phototherapy when applied during the first 24 hours of life in positive Coombs' ABO-incompatible neonates was associated with a significant decrease in TSB at 24 and 48 hours of life but not at 72 and 96 hours.
Significant clinical jaundice was defined by Bhutani et al. 8 as hyperbilirubinemia with TSB Z95th percentile corrected for postnatal age. Based on their data, the probability of subsequent severe hyperbilirubinemia was increased from two-to three-fold if the predischarge TSB was Z95th percentile. A new hour-specific serum bilirubin nomogram for infants with hemolysis has been recommended by the American Academy of Pediatrics (AAP). 12 It is largely similar to the nomogram that was used in the Method section of this present study.
In our study, the number of patients in whom TSB was Z95th percentile was significantly lower in the prophylactic group at 24 hours of life but not later on. A recent evidence-based review showed that phototherapy had an absolute risk-reduction rate of 10 to 17% for prevention of hyperbilirubinemia in healthy jaundiced infants. 9 Our study demonstrated a similar reduction of 15%. The absence of difference in number of hyperbilirubinemic patients between 48 and 96 hours was explained by the initiation of early rescue phototherapy within the first 24 hours in the controls.
Although prophylactic phototherapy was associated with lower bilirubin levels during the first 48 hours of life, we believe that such strategy would not lead to a significant clinical benefit for the following reasons: first, it was noted that 68% of the controls did not need phototherapy, so a significant number of infants in the prophylactic group received phototherapy needlessly. Second, the difference in TSB between the two groups was not clinically significant beyond 48 hours of life. Third, the majority of controls (65%) who had prolonged hospital stay were discharged by 72 hours of life. Fourth, the readmission rate for hyperbilirubinemia was not significantly different between the two groups.
We found that cord TSB Z4 mg/dl (Z68 mmol/l) was highly specific of subsequent hyperbilirubinemia. Risemberg et al. 13 found that all ABO-incompatible newborns in whom the cord bilirubin was greater than 4 mg/dl developed severe hyperbilirubinemia with TSB >16 mg/dl at 12 to 36 hours. Other investigators showed similar results.
14,15 Prophylactic phototherapy was previously recommended for newborns with cord TSB Z4 mg/dl. 11 However, as it is shown in Table 3 , cord TSB Z4 mg/dl has a very low sensitivity, with a high level of false-negative cases. We found that the best predictor of hyperbilirubinemia at Z48 hours of life was the 24-hour TSB when it was Z8 mg/dl.
These results support the necessity for routine predischarge measurement of TSB at 24 hours in ABO affected infants. Predischarge measurement of the bilirubin level and/or assessment of clinical risk factors were strongly recommended by the AAP. 12 Alpay et al. 16 demonstrated that a critical bilirubin level of 6 mg/dl in the first 24 hours of life predicted nearly all of term newborns who developed subsequently significant hyperbilirubinemia.
Limitations to our study may be the selection of patients who were only quasirandomly distributed. Secondly, we retrospectively calculated the ideal sample size to detect the effect of phototherapy to decrease the TSB from 32 to 17% with 5% level of significance and 80% power. The ideal sample size for this study is around 270, which is slightly higher than our sample size (242).
In conclusion, prophylactic phototherapy in positive Coombs' test ABO-incompatible newborns was associated with a significant decrease in TSB within the first 48 hours of life; however, it did not result in a sustained clinical benefit. Hence, our results do not support the use of prophylactic phototherapy in babies with ABO incompatibility and a positive DCT. Frequent monitoring of TSB and early rescue phototherapy was an acceptable management strategy for these patients. TSB Z8 mg/dl at 24 hours of life was the best predictor of hyperbilirubinemia at Z48 hours of life. 
